Yusuke Okuma

4.1k total citations
186 papers, 2.5k citations indexed

About

Yusuke Okuma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Yusuke Okuma has authored 186 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 104 papers in Pulmonary and Respiratory Medicine and 36 papers in Neurology. Recurrent topics in Yusuke Okuma's work include Lung Cancer Treatments and Mutations (84 papers), Cancer Immunotherapy and Biomarkers (52 papers) and Lung Cancer Research Studies (45 papers). Yusuke Okuma is often cited by papers focused on Lung Cancer Treatments and Mutations (84 papers), Cancer Immunotherapy and Biomarkers (52 papers) and Lung Cancer Research Studies (45 papers). Yusuke Okuma collaborates with scholars based in Japan, United States and United Kingdom. Yusuke Okuma's co-authors include Yukio Hosomi, Taiki Hakozaki, Jumpei Kashima, Tatsuru Okamura, Sadamu Homma, Yuichiro Ohe, Kageaki Watanabe, Rui Kitadai, Yukiko Sagawa and Tsunekazu Hishima and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Yusuke Okuma

173 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yusuke Okuma Japan	24	1.6k	936	549	395	293	186	2.5k
Dwight H. Owen United States	22	1.4k 0.9×	651 0.7×	289 0.5×	158 0.4×	270 0.9×	110	1.9k
Laura Pala Italy	18	1.3k 0.9×	523 0.6×	348 0.6×	122 0.3×	525 1.8×	66	2.1k
Valérie Hervieu France	29	1.3k 0.8×	483 0.5×	378 0.7×	504 1.3×	182 0.6×	141	2.8k
Leyre Zubiri United States	22	1.3k 0.8×	450 0.5×	402 0.7×	81 0.2×	329 1.1×	56	2.0k
Andrew J. Plodkowski United States	25	2.5k 1.6×	1.9k 2.0×	909 1.7×	94 0.2×	388 1.3×	85	3.7k
Dennis Cooper United States	27	1.1k 0.7×	367 0.4×	461 0.8×	140 0.4×	466 1.6×	112	2.8k
Kirtee Raparia United States	22	483 0.3×	755 0.8×	288 0.5×	101 0.3×	193 0.7×	58	1.7k
Veronica Mollica Italy	29	1.5k 0.9×	1.6k 1.7×	853 1.6×	70 0.2×	275 0.9×	155	3.0k
A Mussi Italy	26	956 0.6×	1.2k 1.2×	1.1k 2.0×	142 0.4×	82 0.3×	61	2.5k
William J. Edenfield United States	19	783 0.5×	741 0.8×	674 1.2×	74 0.2×	187 0.6×	101	2.1k

Countries citing papers authored by Yusuke Okuma

Since Specialization

Citations

This map shows the geographic impact of Yusuke Okuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuke Okuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuke Okuma more than expected).

Fields of papers citing papers by Yusuke Okuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusuke Okuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuke Okuma. The network helps show where Yusuke Okuma may publish in the future.

Co-authorship network of co-authors of Yusuke Okuma

This figure shows the co-authorship network connecting the top 25 collaborators of Yusuke Okuma. A scholar is included among the top collaborators of Yusuke Okuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuke Okuma. Yusuke Okuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Niho, Seiji, Jun Sato, Miyako Satouchi, et al.. (2024). Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial. Lung Cancer. 191. 107557–107557. 6 indexed citations

Yoshida, Tatsuya, Jumpei Kashima, Masayuki Shirasawa, et al.. (2024). Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression. Lung Cancer. 191. 107788–107788.

Horinouchi, Hidehito, Yuki Shinno, Yusuke Okuma, et al.. (2024). Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy. Clinical Lung Cancer. 25(7). e369–e378.e3. 2 indexed citations

Matsumoto, Yuji, Jumpei Kashima, Tatsuya Imabayashi, et al.. (2023). Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma. Translational Lung Cancer Research. 12(6). 1245–1255. 4 indexed citations

Yoshida, Tatsuya, Shigehiro Yagishita, Yuji Matsumoto, et al.. (2023). Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. JTO Clinical and Research Reports. 4(4). 100474–100474. 3 indexed citations

Yagishita, Shigehiro, Yoshiharu Hayashi, Yuki Takeyasu, et al.. (2023). Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 178. 247–253. 1 indexed citations

Kage, Hidenori, Katsutoshi Oda, Manabu Muto, et al.. (2023). Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan. Cancer Science. 114(7). 3041–3049. 7 indexed citations

Horinouchi, Hidehito, Shigehiro Yagishita, Hirofumi Utsumi, et al.. (2023). Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles. Thoracic Cancer. 14(29). 2909–2923. 2 indexed citations

Naito, Tomoyuki, Hibiki Udagawa, Kōichi Goto, et al.. (2022). Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy. Cancer Science. 114(2). 630–639. 6 indexed citations

10.

Kohno, Takashi, Mamoru Kato, Shinji Kohsaka, et al.. (2022). C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan. Cancer Discovery. 12(11). 2509–2515. 94 indexed citations

11.

Shibaki, Ryota, Tatsuya Yoshida, Shuji Murakami, et al.. (2022). Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients. Clinical Lung Cancer. 23(6). 477–486. 13 indexed citations

12.

Shaikh, Fyza Y., James R. White, Joell J. Gills, et al.. (2021). A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. Clinical Cancer Research. 27(9). 2571–2583. 27 indexed citations

13.

Toyozawa, Ryo, Kota Itahashi, Yutaka Fujiwara, et al.. (2021). 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703). Annals of Oncology. 32. S1002–S1003. 4 indexed citations

14.

Horinouchi, Hidehito, Ken Masuda, Yuki Shinno, et al.. (2021). Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. Cancer Immunology Immunotherapy. 71(3). 737–746. 6 indexed citations

15.

Horinouchi, Hidehito, Tatsuya Yoshida, Ken Masuda, et al.. (2021). Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer. Respiratory Investigation. 60(2). 234–240. 10 indexed citations

16.

Satoh, Hironori, Yusuke Okuma, Jumpei Kashima, et al.. (2021). Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma. OncoTargets and Therapy. Volume 14. 2911–2915. 1 indexed citations

17.

Hakozaki, Taiki, Corentin Richard, Arielle Elkrief, et al.. (2020). The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(10). 1243–1250. 216 indexed citations

18.

Shirasawa, Masayuki, Tatsuya Yoshida, Yuji Matsumoto, et al.. (2020). Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. European Journal of Cancer. 140. 28–36. 15 indexed citations

19.

Masuda, Ken, Hidehito Horinouchi, Midori Tanaka, et al.. (2020). Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Journal of Cancer Research and Clinical Oncology. 147(1). 245–251. 53 indexed citations

20.

Okuma, Yusuke, Yasushi Goto, Fumiyoshi Ohyanagi, et al.. (2020). Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma. Cancer Medicine. 9(20). 7418–7427. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact